EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Lundbeck terminated development of Lu AF35700 in the wake of the failure of the drug in patients with schizophrenia. Release 

> Analysts at Jefferies raised their price target for Genmab after reviewing the prospects of its pipeline programs. Genmab reported first-half results this week. Statement 

> The Dementia Discovery Fund invested £6.5 million ($7.9 million) in AstronauTx, a startup that aims to treat Alzheimer’s disease by targeting astrocytes. Release 

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> AC Immune entered into a neurodegenerative disease research collaboration with the University of Pennsylvania. Statement 

> Scotland’s Synpromics accepted a takeover offer from AskBio. Release 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.